Elsevier

Journal of Clinical Lipidology

Volume 10, Issue 1, January–February 2016, Pages 72-81.e1
Journal of Clinical Lipidology

Original Article
Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study

https://doi.org/10.1016/j.jacl.2015.09.006Get rights and content

Highlights

  • We examine the association between vitamin D (25[OH]D) and an extended lipid panel.

  • We compare deficient 25(OH)D.

  • We adjust for age, sex, HbA1c, insulin, creatinine, and blood urea nitrogen.

  • Deficient 25(OH)D is associated with 5% lower high-density lipoprotein cholesterol.

  • Deficient 25(OH)D is associated with 9% to 26% higher atherogenic lipids.

Background

Cross-sectional studies have found an association between deficiencies in serum vitamin D, as measured by 25-hydroxyvitamin D (25[OH]D), and an atherogenic lipid profile. These studies have focused on a limited panel of lipid values including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG).

Objective

Our study examines the relationship between serum 25(OH)D and an extended lipid panel (Vertical Auto Profile) while controlling for age, gender, glycemic status, and kidney function.

Methods

We used the Very Large Database of Lipids, which includes US adults clinically referred for analysis of their lipid profile from 2009 to 2011. Our study focused on 20,360 subjects who had data for lipids, 25(OH)D, age, gender, hemoglobin A1c, insulin, creatinine, and blood urea nitrogen. Subjects were split into groups based on serum 25(OH)D: deficient (<20 ng/mL), intermediate (≥20–30 ng/mL), and optimal (≥30 ng/mL). The deficient group was compared to the optimal group using multivariable linear regression.

Results

In multivariable-adjusted linear regression, deficient serum 25(OH)D was associated with significantly lower serum HDL-C (−5.1%) and higher total cholesterol (+9.4%), non–HDL-C (+15.4%), directly measured LDL-C (+13.5%), intermediate-density lipoprotein cholesterol (+23.7%), very low–density lipoprotein cholesterol (+19.0%), remnant lipoprotein cholesterol (+18.4%), and TG (+26.4%) when compared with the optimal group.

Conclusion

Deficient serum 25(OH)D is associated with significantly lower HDL-C and higher directly measured LDL-C, intermediate-density lipoprotein cholesterol, very low–density lipoproteins cholesterol, remnant lipoprotein cholesterol, and TG. Future trials examining vitamin D supplementation and cardiovascular disease risk should consider using changes in an extended lipid panel as an additional outcome measurement.

Introduction

Atherosclerotic cardiovascular disease (CVD) is the leading cause of death and disability-adjusted life years lost worldwide.1 Elevated serum concentrations of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) and low concentrations of high-density lipoprotein cholesterol (HDL-C) are known to be major risk factors for developing CVD.2, 3, 4, 5 A growing body of cross-sectional evidence indicates that blood levels of vitamin D, a fat-soluble vitamin, are inversely associated with an atherogenic lipid profile.6, 7, 8, 9 These studies have found that individuals with low serum 25-hydroxyvitamin D (25[OH]D) (defined as either <20 ng/mL,6 <30 ng/mL,7 or in the lowest quartile8) have higher LDL-C, higher TG, and lower HDL-C compared with those with higher levels of 25(OH)D (defined as ≥30 ng/mL6, 7 or higher quartiles8). Serum 25(OH)D is considered the best indicator for vitamin D status.10 Lower serum levels of 25(OH)D are also independently associated with CVD events and mortality, even after adjusting for traditional risk factors including hyperlipidemia, diabetes, hypertension, smoking, body mass index (BMI), and prior history of myocardial infarction.11, 12, 13, 14, 15, 16, 17, 18, 19, 20 The impact of vitamin D supplementation on CVD risk reduction remains inconclusive and is a subject of much investigation and debate.21

Past studies examining the association between 25(OH)D and atherogenic lipid profiles used Friedewald-estimated LDL-C (LDL-Cf), which is less accurate than directly measured LDL-C (LDL-Cd), especially in the setting of low LDL-C and high TG.22 LDL also consists of different densities, with small, dense LDL suggested as a more significant CVD risk factor than large, buoyant LDL particles.23 The overall LDL particle density can be determined using the logarithmic LDL density ratio (LLDR), which is the ratio of dense-to-buoyant LDL subclasses (defined as ln[{LDL3-C + LDL4-C}/{LDL1-C + LDL2-C}]).24 Higher values of LLDR indicate denser LDL, which is potentially more atherogenic. No studies have examined associations between 25(OH)D and LDL-Cd or LDL density. Similarly, no studies have evaluated the relationship between 25(OH)D and remnant lipoprotein cholesterol (RLP-C). RLP-Cs are TG-rich lipoproteins consisting of intermediate-density lipoprotein cholesterol (IDL-C) and dense forms of very low–density lipoprotein cholesterol (VLDL-C). RLP-C has been independently associated with the development of CVD.25, 26, 27, 28, 29, 30

Our study set out to examine the association of vitamin D deficiency, as defined by serum 25(OH)D < 20 ng/mL,31 with an extended lipid panel (Vertical Auto Profile [VAP]) including HDL-C, total cholesterol (TC), non–HDL-C, LDL-Cf, LDL-Cd, IDL-C, VLDL-C, RLP-C, TG, and LLDR in a large cohort representative of the general US population. The inability of randomized controlled trials and cross-sectional studies to thus far agree on the associations between 25(OH)D and CVD risk may be due to confounders, such as glycemic status and kidney function that were not accounted for in prior cross-sectional studies. Current literature suggests there is an inverse association between 25(OH)D and incidence of type II diabetes,32 insulin resistance,33, 34 and glycosylated hemoglobin.35, 36, 37 Given the link between diabetes and CVD,38 our study sought to control for glycemic status in our analysis. Previous research has also shown an association between 25(OH)D and kidney function,39, 40, 41 necessitating controlling for kidney function in our study given the link between declining kidney function and increasing risk for CVD.42, 43 Our study also adjusted for age and gender in addition to glycemic status and kidney function. By using this database with directly measured lipid values and adjusting for clinical variables, we can further elucidate the relationship between 25(OH)D and lipids with greater power than prior studies. We hypothesized that 25(OH)D deficiency would be associated with a more atherogenic lipid profile.

Section snippets

Study population

Data in the Very Large Database of Lipids (VLDL) database were collected from 1,340,614 adults (≥18 years of age) in the United States who were clinically referred for VAP (Atherotech, Inc, Birmingham, AL) ultracentrifugation testing for lipid profiles from 2009 to 2011. The distribution of lipid values in this data set matches the distribution in the National Health and Nutrition Examination Survey 2007 to 2008.44 For the primary analysis, we used a cohort of 20,360 individuals from the VLDL

Results

Our final study cohort consisted of 20,360 subjects whose baseline characteristics are listed as median and interquartile range in Table 1. This cohort has similar distributions of age, TC, HDL-C, LDL-Cf, LDL-Cd, and TG compared to all subjects in the VLDL database with a 25(OH)D measurement (n = 70,207) and to all subjects included in the entire VLDL database (n = 1,340,614). There was a greater proportion of women in both our study subset (57.7%) and the entire VLDL subset with 25(OH)D

Discussion

In one of the largest and most detailed studies investigating the association between serum 25(OH)D and lipids, we find that 25(OH)D deficiency is associated with an atherogenic lipid profile across all lipid outcomes examined. Individuals with deficient 25(OH)D have on average 8.4% to 42.2% more of the various atherogenic lipids and 10.4% less HDL-C compared with individuals with optimal serum 25(OH)D. After adjusting for age, gender, glycemic status, and kidney function, 25(OH)D-deficient

Limitations

The study has several limitations. As we do not have access to patient medical records, medication usage, including whether patients were taking vitamin D supplements or not, is unknown. Individuals with favorable health-seeking behavior might be more likely to take vitamin D supplements. Although conversely, older, frailer individuals who are at risk for osteoporosis or osteopenia may also be taking vitamin D supplements. The use of 25(OH)D in our analysis, which integrates sunlight, diet, and

Future directions

The limitations discussed previously do not diminish the role of our study in generating hypotheses for future investigations. Prior observational studies have found links between deficient 25(OH)D and CVD risk, but the mechanism remains unclear.11, 12, 13, 14, 15, 16, 17, 18, 19, 20 Our results indicate that the mechanism by which deficient 25(OH)D increases CVD risk may be mediated through changes in lipids. Our study and others suggest it is likely that only deficient individuals (rather

Conclusions

Despite inconclusive evidence from clinical trials, there remains strong evidence in the literature that 25(OH)D is inversely associated with LDL-Cf and TG and directly associated with HDL-C. Our study not only supports these findings but also shows for the first time, to the best of our knowledge that this inverse association holds true for LDL-Cd, IDL-C, VLDL-C, and RLP-C. Investigators conducting future clinical trials examining the impact of vitamin D supplementation on hyperlipidemia and

Acknowledgment

Atherotech provided the investigators with de-identified data generated from commercial lipid analyses and did not provide payments for the research or article writing and did not participate in data analysis or influence the conclusions. This study was initiated by the investigators and did not receive any specific funding. The authors take responsibility for the accuracy of the statistical analyses and had the sole authority on article preparation and submission for publication.

References (68)

  • J.C. Kovacic et al.

    The relationships between cardiovascular disease and diabetes: focus on pathogenesis

    Endocrinol Metab Clin North Am

    (2014)
  • Y.J. Tak et al.

    The relationship between the level of serum 25-hydroxyvitamin d and renal function in patients without chronic kidney disease: a cross-sectional study

    J Ren Nutr

    (2015)
  • E.M. Kaptein et al.

    Serum 25-hydroxyvitamin D deficiency: a risk factor for chronic kidney disease in ambulatory indigent patients

    Endocr Pract

    (2014)
  • M.J. Damasiewicz et al.

    Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD

    Am J Kidney Dis

    (2013)
  • K.R. Kulkarni

    Cholesterol profile measurement by vertical auto profile method

    Clin Lab Med

    (2006)
  • J. Wortsman et al.

    Decreased bioavailability of vitamin D in obesity

    Am J Clin Nutr

    (2000)
  • J.L. Perez-Castrillon et al.

    Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease

    Am J Cardiol

    (2007)
  • J.A. Ford et al.

    Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis

    Am J Clin Nutr

    (2014)
  • R. Jorde et al.

    Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids

    Prog Lipid Res

    (2011)
  • J. Pekkanen et al.

    Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease

    N Engl J Med

    (1990)
  • P. McBride

    Triglycerides and risk for coronary artery disease

    Curr Atheroscler Rep

    (2008)
  • D.J. Gordon et al.

    High-density lipoprotein—the clinical implications of recent studies

    N Engl J Med

    (1989)
  • M.P. Ponda et al.

    Vitamin D may not improve lipid levels: a serial clinical laboratory data study

    Circulation

    (2012)
  • R. Jorde et al.

    High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile

    Eur J Clin Nutr

    (2010)
  • T. Skaaby et al.

    Vitamin D status and changes in cardiovascular risk factors: a prospective study of a general population

    Cardiology

    (2012)
  • E. Giovannucci et al.

    25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study

    Arch Intern Med

    (2008)
  • T.J. Wang et al.

    Vitamin D deficiency and risk of cardiovascular disease

    Circulation

    (2008)
  • K. Kienreich et al.

    Vitamin D and cardiovascular disease

    Nutrients

    (2013)
  • R. Chowdhury et al.

    Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies

    BMJ

    (2014)
  • E. Theodoratou et al.

    Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials

    BMJ

    (2014)
  • L. Wang et al.

    Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies

    Circ Cardiovasc Qual Outcomes

    (2012)
  • M.L. Melamed et al.

    25-hydroxyvitamin D levels and the risk of mortality in the general population

    Arch Intern Med

    (2008)
  • J.E. Manson et al.

    Vitamin D research and clinical practice: at a crossroads

    JAMA

    (2015)
  • H.M. Ahmed et al.

    Ratio of dense to buoyant LDL subclass is associated with LDL density phenotype (VLDL-5)

    Open Chem Biomed Methods J

    (2013)
  • Cited by (76)

    • Vitamin D deficiency and metabolic syndrome—Is there a causality?

      2023, Metabolic Syndrome: From Mechanisms to Interventions
    View all citing articles on Scopus
    View full text